Payment overview · 2025
General Payments
$194.64
10 reported records · 6 companies
Healthcare provider profile · identity verified
Joel E Nachimson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1922040633
Verified facts
What the public records show
CMS Open Payments records show Joel E Nachimson, M.D. received $194.64 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.04 | 22.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.83 | 19.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.15 | 18.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.08 | 15.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.75 | 14.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.79 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.64 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 30 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 604 | 176 |
| Atorvastatin Calcium | Atorvastatin Calcium | 474 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 347 | 115 |
| Metformin Hcl | Metformin Hcl | 242 | 78 |
| Metformin Hcl Er | Metformin Hcl | 238 | 74 |
| Losartan Potassium | Losartan Potassium | 235 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 81 |
| Trazodone Hcl | Trazodone Hcl | 213 | 63 |
| Lisinopril | Lisinopril | 212 | 70 |
| Simvastatin | Simvastatin | 204 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 61 |
| Valsartan | Valsartan | 180 | 50 |
| Alprazolam | Alprazolam | 178 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 61 |
| Gabapentin | Gabapentin | 168 | 54 |
| Omeprazole | Omeprazole | 166 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 60 |
| Glipizide Er | Glipizide | 125 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 44 |
| Carvedilol | Carvedilol | 121 | 36 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 120 | 40 |
| Montelukast Sodium | Montelukast Sodium | 116 | 37 |
| Allopurinol | Allopurinol | 114 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 24 |
| Donepezil Hcl | Donepezil Hcl | 93 | 27 |
| Furosemide | Furosemide | 90 | 33 |
| Azithromycin | Azithromycin | 87 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 21 |
| Glimepiride | Glimepiride | 73 | 19 |
| Meloxicam | Meloxicam | 70 | 24 |
| Tramadol Hcl | Tramadol Hcl | 70 | 21 |
| Rybelsus | Semaglutide | 65 | 15 |
| Jardiance | Empagliflozin | 62 | 21 |
| Ozempic | Semaglutide | 60 | 20 |
| Sertraline Hcl | Sertraline Hcl | 60 | 20 |
| Clonazepam | Clonazepam | 59 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 15 |
| Potassium Chloride | Potassium Chloride | 56 | 23 |
| Ezetimibe | Ezetimibe | 55 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 17 |
| Synthroid | Levothyroxine Sodium | 54 | 16 |
| Famotidine | Famotidine | 52 | 19 |
| Fenofibrate | Fenofibrate | 51 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 15 |
| Lactulose | Lactulose | 48 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Ibuprofen | Ibuprofen | 46 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 16 |
| Finasteride | Finasteride | 45 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 14 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 13 |
| Atenolol | Atenolol | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 37 | 12 |
| Eliquis | Apixaban | 36 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 24 |
| Diazepam | Diazepam | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Glipizide | Glipizide | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 13 |
| Methylprednisolone | Methylprednisolone | 31 | 20 |
| Spironolactone | Spironolactone | 31 | 11 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 20 |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 24 |
| Fluconazole | Fluconazole | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Colchicine | Colchicine | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Diflunisal | Diflunisal | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $194.64 · 10 records | PFIZER INC. | AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, NURTEC ODT, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY, Veozah, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error